Beneficial Role of Vitamin D in Dengue Fever

Beneficial Role of Vitamin D Supplementation and Clinical Outcomes in Patients with Dengue Fever - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059167

Enrollment

Registered

2023-10-26

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A90- Dengue fever [classical dengue] Health Condition 2: A91- Dengue hemorrhagic fever

Interventions

Intervention1: Vitamin D (Cholecalciferol) 2000 IU Tablets: Interventional group will receive Vitamin D (Cholecalciferol) 2000 IU Tablets at, Dose - 2000 IU per Day, Route of Administration - Oral,

Eligibility

Inclusion criteria

Inclusion criteria: Patient admitted in MGMCRI with Dengue NS1 Antigen Positive, tested by Rapid Card Test, Irrespective of IgM, IgG Status Both Male and Female Patients in the Age Group - 18 to 60 Yrs Patients with Warning Signs, Bleeding Manifestations, Vascular Leak can also be included

Exclusion criteria

Exclusion criteria: Patients having Comorbidities except Diabetes Mellitus & Systemic Hypertension Patients with other co infections like scrub typhus and malaria Patient with Thrombotic thrombocytopenic purpura, Hemolytic uremic syndrome Patient with Disseminated intravascular coagulation, Idiopathic thrombocytopenic purpura Patient on Antiplatelets Drugs and Anticoagulants Patient requiring Platelets transfusion Chronic Kidney or liver Diseases Pregnancy and Lactating Mother Vulnerable Population including Children and Elderly Population

Design outcomes

Primary

Measure	Time frame
To study the effect of Oral Vitamin D Supplementation at 2000 IU per Day in reducing the progression to severe dengueTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge	—

Secondary

Measure	Time frame
To compare Lab investigations (including Platelet count, Total count, Hematocrit, Mean platelet volume, Platelet distribution width), between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the development of complications of Dengue (such as Vascular leak, ARDS, Bleeding Manifestations, Shock), between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the Duration of Hospital Stay, Duration of ICU Stay, between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the Need for Intensive Care, Ventilator Requirement, between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge	—

Measure

Time frame

To compare Lab investigations (including Platelet count, Total count, Hematocrit, Mean platelet volume, Platelet distribution width), between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the development of complications of Dengue (such as Vascular leak, ARDS, Bleeding Manifestations, Shock), between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the Duration of Hospital Stay, Duration of ICU Stay, between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge;To compare the Need for Intensive Care, Ventilator Requirement, between the interventional & control groupsTimepoint: Assessed on Day 0, Day 5, Day 10 or At Time of Discharge

—

Countries

India

Contacts

Public ContactDr Subramanian Mariselvan S

Mahatma Gandhi Medical College and Research Institute

sivagreen.dr@gmail.com9894444774

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026